148
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis.

      Transplantation
      Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, administration & dosage, Humans, Kidney Transplantation, Liver Transplantation, Male, Middle Aged, Organ Transplantation, Pancreas Transplantation, Postoperative Complications, drug therapy, Protein C, Recombinant Proteins, Sepsis, etiology

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Severe sepsis in immunosuppressed recipients of solid-organ transplants is associated with a high mortality. Conventional management of sepsis in this patient population has not specifically attempted to treat the underlying inflammatory or procoagulant responses that contribute to the development of multisystem organ failure. Drotrecogin alfa (activated, human activated protein C) has been shown to be a safe and effective adjuvant in the treatment of severe sepsis; however, experience in recipients of solid-organ transplants has not been addressed. The treatments and outcomes of three solid-organ transplant recipients (liver, kidney, and kidney-pancreas) who experienced episodes of severe sepsis are presented and demonstrate initial success with the use of drotrecogin alfa (activated).

          Related collections

          Author and article information

          Comments

          Comment on this article